China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday that they have found two more countries to conduct late-stage clinical testing of coronavirus vaccine candidates.
According to Reuters, Serbia and Pakistan, while agreeing to participate in the Phase 3 trials of candidate vaccines cnbg'n, Sinovac received approval from Turkey and Bangladesh.
The two companies sought more data from other countries as new cases in China decreased.
The company told Reuters that Serbia will test two vaccines developed by CNBG's Wuhan and Beijing units and will test the candidate of Pakistan's Beijing unit.
CNBG vice president Zhang Yuntao said CNBG's phase 3 trials are expected to cover 10 people in nearly 50.000 countries. Trials have already started in the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan.
300 MILLION DOSES PRODUCTION PER YEAR
Zhang said that foreign countries are interested in ordering a total of 500 million doses of vaccines.
Zhang said that CNBG is expected to produce 300 million doses of vaccine annually after upgrading its manufacturing techniques and is working on a plan to increase annual capacity to 1 billion doses.
He added that the company will soon begin to provide vaccinations to Chinese staff working in overseas embassies and consulates.
Sinovac CEO Yin Weidong told Reuters on Sunday, Sinovac's vaccine candidate tested in Brazil and Indonesia, he said coronavac receive confirmation from the phase 3 trials for Turkey and Bangladesh.
While the final phase of trials is still underway to prove that vaccines are safe and effective, China has authorized vaccine candidates from Sinovac and CNBG for emergency use for those in high-risk groups such as medical workers.
Source: China International Radio